Johnson Johnson AbbVie: Paths to Pharma Dominance
Johnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
Learn various ways to cut costs on a limited budget. Make smarter financial choices and save effectively.
21,848 articlesJohnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
A new Goldman Sachs note argues that AI’s next growth wave hinges on optical networking, not just faster GPUs. Lument...
With the World Cup 2026 underway, world bets prediction markets are drawing attention not just for odds but for poten...
Adobe has pulled back about 40% from its peak, but new AI-driven products and expanding ARR are reinvigorating the bu...
A sharp intraday drop in Micron shares sparked by AI memory demand concerns set off a broader discussion about pricin...
Korean chip equities are wavering after a blistering AI-driven rally, with the KOSPI retreating and memory peers weig...
As volatility climbs in 2026, SPYI and JEPI compete for monthly income. SPYI bets on higher yields with derivative in...
Lucid shares sank as new reports claim the EV maker is weighing drastic options, including a take-private or Chapter ...
A high-stakes pivot: the team behind ethereum's institutional privacy push launches EthSystems, a for-profit venture ...
IBM shares tumbled 25% after CEO Arvind Krishna acknowledged the company did not adapt fast enough to shifting demand...
A new AI-based forecast linked to Elon Musk’s Grok model signals a 15-25% Netflix jump within 30 days, centering on a...
Abbott Laboratories moved higher after boosting its profit outlook and signaling strength across its diagnostics and ...